• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Cervarix--a bivalent L1 virus-like particle vaccine for prevention of human papillomavirus type 16- and 18-associated cervical cancer.
【24h】

Cervarix--a bivalent L1 virus-like particle vaccine for prevention of human papillomavirus type 16- and 18-associated cervical cancer.

机译：Cervarix-一种预防人乳头瘤病毒16型和18型宫颈癌的二价L1病毒样颗粒疫苗。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Cervical cancer continues to have a devastating impact on women worldwide. An estimated 470,000 women are diagnosed with the disease every year and, of these, > 230,000 die from it. Recent decades have witnessed considerable advances in our understanding of cervical carcinogenesis, in particular the causal role that oncogenic human papillomavirus infection plays in its etiology. In countries that lack organized cervical screening programs, prophylactic vaccination against human papillomavirus may offer the most effective way of reducing mortality from the disease. Cervarix, a bivalent L1 virus-like particle vaccine targeted against human papillomavirus types 16 and 18, has been developed to address this possibility. The clinical experience of Cervarix and its potential role in reducing the global burden of cervical cancer is discussed.
机译：宫颈癌继续对全世界的妇女造成毁灭性影响。每年估计有470,000名妇女被诊断出患有这种疾病，其中有23万多人死于这种疾病。最近几十年来，我们对子宫颈癌发生的理解取得了长足的进步，特别是致癌性人乳头瘤病毒感染在其病因中起着因果作用。在缺乏有组织的宫颈筛查项目的国家，针对人乳头瘤病毒的预防接种可能是降低疾病死亡率的最有效方法。针对这种可能性，已经开发出了针对人乳头瘤病毒16型和18型的二价L1病毒样颗粒疫苗Cervarix。讨论了Cervarix的临床经验及其在减轻子宫颈癌全球负担中的潜在作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号